BioWorld

March 7, 2006

View Archived Issues

DNA Strand Segregation Joins List Of Nonrandom Processes

Read More

MannKind’s Inhaled Insulin In Phase III Efficacy Studies

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Infinity, Novartis In $400M Deal For Inhibitors Of Bcl-2

Tackling a family of proteins linked to cancer but long considered undruggable, Infinity Pharmaceuticals Inc. and Novartis AG signed a global development and commercialization deal potentially worth more than $400 million. (BioWorld Today) Read More

Heading To Clinic, Nereus Adds $18.3M To Series D

Read More